Physician profile
Lesle D Long
NPI 1528045069
$1,878.20
in general payments reported to CMS, 2019-2025
27 companies · $355 in 2025
The $355 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $87.78 · 2020: $205 · 2021: $202 · 2022: $237 · 2023: $309 · 2024: $481 · 2025: $355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,145.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,145.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $183.83 | 2019-2024 | Xifaxan |
| Abbvie INC. | $176.76 | 2021-2024 | |
| Phathom Pharmaceuticals, INC. | $169.79 | 2024-2025 | Voquezna |
| Braeburn INC. | $168.40 | 2024-2025 | Brixadi |
| Novo Nordisk INC | $165.49 | 2020-2025 | Ozempic, Rybelsus, Tresiba |
| Pfizer INC. | $115.06 | 2023-2025 | |
| Exact Sciences Corporation | $114.42 | 2023-2024 | Cologuard Collection Kit |
| Indivior INC. | $107.51 | 2019-2025 | Sublocade |
| Amgen INC. | $75.34 | 2021-2024 | Otezla, Repatha |
| Antares Pharma, INC. | $71.29 | 2020-2025 | Xyosted |
| Lilly USA, LLC | $59.66 | 2022-2025 | Mounjaro |
| Novartis Pharmaceuticals Corporation | $52.17 | 2022-2024 | |
| Biohaven Pharmaceutical Holding Company LTD. | $46.58 | 2022 | |
| Daiichi Sankyo INC. | $44.97 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $44.71 | 2021-2023 | Trintellix |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dexcom, INC. | $40.54 | 2022 | |
| Allergan, INC. | $38.60 | 2020 | |
| Astrazeneca Pharmaceuticals LP | $29.73 | 2019-2020 | |
| Shire North American Group INC | $26.25 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $26.24 | 2022-2024 | Livalo |
| Inari Medical, INC. | $22.41 | 2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Boston Scientific Corporation | $18.53 | 2021 | |
| Mayne Pharma Commercial LLC | $18.08 | 2025 | |
| Esperion Therapeutics, INC. | $17.53 | 2021 | |
| Tolmar, INC. | $16.46 | 2023 | |
| Paratek Pharmaceuticals, INC. | $14.74 | 2023 | Nuzyra |
| Eisai INC. | $13.11 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lesle Long listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.